Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05258279 | Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | completed | Phase 2 | 30 | Juntendo UniversityOTHER | 1 | Jul 29, 2026 |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT04084717 | Study of Crizotinib for ROS1 and MET Activated Lung Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT02955758 | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | completed | Phase 2 | 25 | Joel NealOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04173507 | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | completed | Phase 2 | 47 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT03904563 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04201756 | Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma | completed | Phase 2 | 47 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT00152477 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | completed | Phase 2 | 165 | UCB PharmaINDUSTRY | 3 | Apr 12, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT02303977 | Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy | completed | Phase 2 | 37 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01532089 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 88 | Academic and Community Cancer Research UnitedOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01260181 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01174563 | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01829113 | Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer(Spruce) | completed | Phase 2 | 155 | SCRI Development Innovations, LLCOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT02979821 | Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | completed | Phase 2 | 6 | Korean Association for the Study of Targeted TherapyOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01378962 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) | completed | Phase 2 | 50 | Hoffmann-La RocheINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00942825 | Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)(CBP08-02) | completed | Phase 2 | 195 | CanBas Co. Ltd.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT01160601 | Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | completed | Phase 2 | 86 | Peregrine PharmaceuticalsINDUSTRY | 5 | Apr 19, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT01070927 | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01496742 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 259 | Genentech, Inc.INDUSTRY | 13 | Sep 23, 2016 | clinicaltrials |
| NCT01519804 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 108 | Genentech, Inc.INDUSTRY | 9 | Sep 2, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT00642473 | A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash(MATER) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 1 | May 23, 2016 | clinicaltrials |
| NCT00518011 | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer. | completed | Phase 2 | 17 | Hoffmann-La RocheINDUSTRY | 1 | May 16, 2016 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials